GenScript Biotech's Impressive Revenue Surge
GenScript Biotech Corporation (HKEX:1548) has announced a remarkable 43.5% increase in revenue, reaching $561.4 million in the first half of 2024. This growth is largely attributed to the success of their CARVYKTI treatment for multiple myeloma, which has outperformed historical CAR-T launches by treating over 3,000 patients.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
